BETA-TT8 Oral

BETA-TT8 Oral is being developed as an oral treatment of systemic inflammation, in particular inflammation of the central nervous system and peripheral nerves.

In laboratory studies, BETA-TT8 readily crosses the blood-brain barrier and the blood-eye barrier following oral dosing.

One therapeutic indication being considered is patients where wet AMD is associated with systemic inflammatory conditions, including rheumatoid arthritis, inflammatory bowel disease, lupus and atherosclerosis.